Methadone and QTc Prolongation in Pain and Palliative Care Patients: A Case Control Study

Authors

Katherine Juba, St. John Fisher UniversityFollow
Tina Khadem, University of Rochester Medical Center
David Hutchinson, St. John Fisher UniversityFollow
Jack Brown, St. John Fisher University

Document Type

Poster Presentation

Publication Date

10-2015

Abstract

Methadone (ME) is commonly used in pain and palliative care (PPC) patients with refractory pain or intolerable opioid adverse effects (AEs). A unique ME AE is its QTc interval prolongation risk but most evidence exists in methadone maintenance therapy (MMT) patients. Our goal was to identify QTc interval prolongation risk factors in PPC patients receiving ME and other medications known to prolong the QTc interval and develop a risk stratification tool.

DOI

https://doi.org/10.1002/phar.1659

Comments

Presented at the American College of Clinical Pharmacy Global Conference on Clinical Pharmacy in San Francisco, California, October 2015.

Abstract published in Pharmacotherapy, Volume 35, Issue 11, Page e202, November 2015: https://doi.org/10.1002/phar.1659

Publication Information

Juba, Katherine; Khadem, Tina; Hutchinson, David; and Brown, Jack (2015). "Methadone and QTc Prolongation in Pain and Palliative Care Patients: A Case Control Study." Pharmacotherapy 35.11, e202-e202.

Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.